Category survey

FFAR4 and nigrostriatal function: A novel target for treatment of PD? Investments < €500k United States of America 2016    

Defining the mechanisms of dipeptide repeat protein toxicity in C9orf72 ALS/FTD Investments < €500k United States of America 2016    

Development of VU0652957 for the treatment of Parkinsons disease (PD) Investments < €500k United States of America 2016    

Therapeutic Potential of Small Molecule Activators of the PINK1-Parkin Pathway Investments < €500k United States of America 2016    

MODELING HUNTINGTONS DISEASE WITH STRIATAL NEURONS DIRECTLY CONVERTED FROM PATIENT FIBROBLASTS Investments < €500k United States of America 2016    

Identification of pathogenic mechanisms important in multiple system atrophy Investments < €500k United States of America 2016    

Cortical Pathophysiology in Mouse Models of Huntingtons Disease Investments < €500k United States of America 2016    

Transposable Elements in Frontotemporal Lobar Degeneration Investments < €500k United States of America 2016    

Disease Mechanisms in Human Ubiquilinopathy Investments < €500k United States of America 2016    

Does Microglial Activation Influence Propagation of Alpha-synuclein Pathology Investments < €500k United States of America 2016    

The role of striatal cholinergic interneurons in Parkinson’s disease Investments < €500k United States of America 2016    

Efficacies and Pharmacodynamic Assays for LRRK2 Small-Molecule Inhibitors Investments < €500k United States of America 2016    

Molecular Basis of TDP-43 Proteinopathies: Disease Models and Mechanisms Investments < €500k United States of America 2016    

Molecular genetic studies of progranulin regulators in FTLD and ALS Investments < €500k United States of America 2016    

Neuronal function of huntingtin associated protein Investments < €500k United States of America 2016    

Structures and mechanisms of nuclear import and export Investments < €500k United States of America 2016    

DEVELOPING A MICRORNA-TARGETED THERAPY FOR ALS Investments < €500k United States of America 2016    

Allele-Selective Inhibitors for Expanded Trinucleotide Repeat Genes Investments < €500k United States of America 2016    

Prokineticin 2 and Neuroinflammatory Mechanisms Investments < €500k United States of America 2016    

Synaptic toxicity of Huntington disease protein Investments < €500k United States of America 2016    

BDNF rs6265 and Response to Dopaminergic Therapy in PD Investments < €500k United States of America 2016    

Defining the mechanistic basis of a prion disaggregase Investments < €500k United States of America 2016    

Role of Mitophagy in Mitochondrial Protein Quality Control Investments < €500k United States of America 2016    

Capacity building in sub-Saharan Africa to conduct cutting-edge genetics research in Parkinsons disease. Investments < €500k United States of America 2016    

Small molecule Parkin activators to treat Alzheimers Disease Investments < €500k United States of America 2016    

ROS driven mitochondrial-telomere dysfunction during environmental stress Investments < €500k United States of America 2016    

Patient Motor Neuron Assay System for ALS Drug Discovery Investments < €500k United States of America 2016    

TDP-43 aggregation inhibitors for the treatment of ALS Investments < €500k United States of America 2016    

A Novel Image Guided System to Mount Micro Targeting Platform for Deep Brain Stimulation Surgery to treat Parkinsons Disease Investments < €500k United States of America 2016    

Retinal neurotoxicity of manganese exposure Investments < €500k United States of America 2016    

Optimization of Bi-Pap and PEG intervention protocols for Amyotrophic Lateral Sclerosis Investments < €500k United States of America 2016    

Somatic inactivation of the SNCA locus: a new approach to the understanding and treatment of Parkinsons Disease Investments < €500k United States of America 2016    

Imaging agents for synucleinopathy drug discovery Investments < €500k United States of America 2016    

Development of a New ALS Mouse Model that Targets Profilin1 and Actin Filaments Investments < €500k United States of America 2016    

Exploring and enhancing Karyopherin beta-2 disaggregate activity Investments < €500k United States of America 2016    

Evaluating AAV-mediated gene replacement for Spinal Muscular Atrophy with Respiratory Distress 1 Investments < €500k United States of America 2016    

Development of mouse models for ALS5 and SPG11 Investments < €500k United States of America 2016    

Noninvasive High-resolution Pediatric Surface EMG Investments < €500k United States of America 2016    

Alpha-Galactosidase A: a novel target for reducing alpha-synuclein toxicity Investments < €500k United States of America 2016    

Pathogenic role of the novel mitochondrial apoptotic protein PSAP in ALS Investments < €500k United States of America 2016    

Glial uptake of dopamine after L-DOPA medication Investments < €500k United States of America 2016    

Autophagy dysfunction in Parkinsons Disease by VPS35 D620N Investments < €500k United States of America 2016    

Neural Substrates of Deterministic Decision Making Investments < €500k United States of America 2016    

Development of protein molecular probes for detection of alpha synuclein oligomeric assemblies Investments < €500k United States of America 2016    

Modifiers of C9orf72 associated dipeptide protein toxicity in a C. elegans model Investments < €500k United States of America 2016    

Airway protection deficits according to stimulus type in Parkinsons disease Investments < €500k United States of America 2016    

NOVEL EXPERIMENTAL PLATFORM FOR PRODOMAL PARKINSONS DISEASE Investments < €500k United States of America 2016    

Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinsons Therapeutic Investments < €500k United States of America 2016    

Striatal CaV1.3 Calcium Channels: An Overlooked Antidyskinetic Target for PD Investments < €500k United States of America 2016    

Understanding the Voice Control System in Parkinsons Disease Investments < €500k United States of America 2016